Noble Financial Predicts GeoVax Labs Q1 Earnings

GeoVax Labs Inc. (NASDAQ:GOVX) – Stock analysts at Noble Financial issued their Q1 2026 earnings estimates for GeoVax Labs in a research report issued on Friday, November 14th. Noble Financial analyst R. Leboyer forecasts that the company will post earnings of ($0.35) per share for the quarter. The consensus estimate for GeoVax Labs’ current full-year earnings is ($4.49) per share. Noble Financial also issued estimates for GeoVax Labs’ Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.47) EPS and Q4 2026 earnings at ($0.55) EPS.

Several other research analysts have also weighed in on the company. Wall Street Zen lowered GeoVax Labs from a “hold” rating to a “sell” rating in a research report on Monday, July 21st. D. Boral Capital restated a “buy” rating and set a $9.00 price target on shares of GeoVax Labs in a research note on Friday, September 26th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of GeoVax Labs in a report on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

GeoVax Labs Trading Down 3.8%

Shares of NASDAQ:GOVX opened at $0.45 on Monday. The firm has a market cap of $13.40 million, a price-to-earnings ratio of -0.22 and a beta of 3.34. GeoVax Labs has a 1 year low of $0.42 and a 1 year high of $3.15. The business has a fifty day simple moving average of $0.59 and a 200 day simple moving average of $0.76.

GeoVax Labs (NASDAQ:GOVX) last issued its earnings results on Thursday, November 13th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.07). GeoVax Labs had a negative net margin of 403.88% and a negative return on equity of 408.80%.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Armistice Capital LLC acquired a new position in shares of GeoVax Labs during the first quarter worth approximately $703,000. Sabby Management LLC bought a new position in GeoVax Labs during the third quarter worth $313,000. Finally, Jane Street Group LLC acquired a new position in GeoVax Labs during the 1st quarter valued at $27,000. 6.09% of the stock is owned by institutional investors.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.